dc.contributor.author | Thompson, Reid C. | |
dc.date.accessioned | 2023-02-02T20:13:10Z | |
dc.date.available | 2023-02-02T20:13:10Z | |
dc.date.issued | 2022-11-17 | |
dc.identifier.citation | Liau LM, Ashkan K, Brem S, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023;9(1):112–121. doi:10.1001/jamaoncol.2022.5370 | en_US |
dc.identifier.issn | 2374-2437 | |
dc.identifier.other | eISSN 2374-2445 | |
dc.identifier.other | PubMed ID36394838 | |
dc.identifier.uri | http://hdl.handle.net/1803/17973 | |
dc.description | Only Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 | en_US |
dc.description.abstract | IMPORTANCE Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.
OBJECTIVE To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax L) to standard of care (SOC) extends survival among patients with glioblastoma.
DESIGN, SETTING, AND PARTICIPANTS This phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.
INTERVENTIONS The active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.
MAIN OUTCOMES AND MEASURES The primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.
RESULTS A total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P < .001). Survival at 24 and 30 months after recurrence was 20.7% vs 9.6% and 11.1% vs 5.1%, respectively. Survival was improved in patients with nGBM with methylated MGMT receiving DCVax-L compared with external control patients (HR, 0.74; 98% CI, 0.55-1.00; P = .03).
CONCLUSIONS AND RELEVANCE In this study, adding DCVax-L to SOC resulted in clinically meaningful and statistically significant extension of survival for patients with both nGBM and rGBM compared with contemporaneous, matched external controls who received SOC alone. | en_US |
dc.description.sponsorship | This study was supported by
Northwest Biotherapeutics, Inc. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | JAMA Oncology | en_US |
dc.rights | This is an open access article distributed under the terms of the CC-BY-NC-ND license, which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
If you are the author of this article and have questions about the Creative Commons license, please contact permissions@jamanetwork.com. | |
dc.source.uri | https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 | |
dc.subject | Double-blind | en_US |
dc.subject | Plus lomustine | en_US |
dc.subject | Temozolomide | en_US |
dc.subject | Bevacizumab | en_US |
dc.subject | Progression | en_US |
dc.title | Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1001/jamaoncol.2022.5370 | |